| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KYNU |
| Uniprot No | Q16719 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-307aa |
| 氨基酸序列 | MEPSSLELPADTVQRIAAELKCHPTDERVALHLDEEDKLRHFRECFYIPKIQDLPPVDLSLVNKDENAIYFLGNSLGLQPKMVKTYLEEELDKWAKIAAYGHEVGKRPWITGDESIVGLMKDIVGANEKEIALMNALTVNLHLLMLSFFKPTPKRYKILLEAKAFPSDHYAIESQLQLHGLNIEESMRMIKPREGEETLRIEDILEVIEKEGDSIAVILFSGVHFYTGQHFNIPAITKAGQAKGCYVGFDLAHAVGNVELYLHDWGVDFACWCSYKYLNAGAGGIAGAFIHEKHAHTIKPARSEFFN |
| 预测分子量 | 61.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KYNU(犬尿氨酸酶)重组蛋白研究的3篇参考文献示例(注：以下为虚构示例，实际文献需通过学术数据库验证)：
1. **文献名称**：重组人源KYNU蛋白的异源表达及酶活性分析
**作者**：Smith J, et al.
**摘要**：本研究在大肠杆菌系统中成功表达了可溶性重组人源KYNU蛋白，并通过镍柱亲和层析纯化。酶动力学实验表明该重组蛋白在体外可高效催化犬尿氨酸转化为邻氨基苯甲酸，为后续代谢疾病机制研究提供工具。
2. **文献名称**：KYNU晶体结构与新型抑制剂的分子对接研究
**作者**：Chen L, et al.
**摘要**：通过X射线晶体学解析了重组KYNU蛋白的3D结构(分辨率2.1Å)，结合计算机模拟筛选出特异性小分子抑制剂。该发现为开发神经炎症相关疾病的靶向药物奠定结构基础。
3. **文献名称**：KYNU重组蛋白在肝癌细胞代谢重编程中的作用
**作者**：Wang Y, et al.
**摘要**：利用HEK293细胞表达体系制备功能性KYNU重组蛋白，实验证明其可通过调节色氨酸代谢通路抑制肝癌细胞增殖，提示KYNU可能成为肿瘤免疫治疗的潜在靶点。
建议通过PubMed或Web of Science搜索真实文献时使用关键词："recombinant kynureninase"、"KYNU expression" 或 "kynureninase purification"。
**Background of KYNU Recombinant Protein**
Kynureninase (KYNU) is a pyridoxal-5'-phosphate (PLP)-dependent enzyme that plays a critical role in the kynurenine pathway, a major route for tryptophan catabolism. It catalyzes the hydrolysis of kynurenine and 3-hydroxykynurenine into anthranilic acid and 3-hydroxyanthranilic acid, respectively, while generating alanine as a byproduct. This pathway is pivotal in regulating immune responses, neurotransmitter synthesis, and inflammation, with metabolites influencing processes such as neuroprotection, neurodegeneration, and immune tolerance.
KYNU’s activity is linked to several pathological conditions, including neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s diseases), cancer, and chronic inflammatory diseases. Dysregulation of KYNU expression or function can alter metabolite levels, contributing to oxidative stress, immune dysregulation, or tumor progression. For instance, reduced KYNU activity may lead to accumulation of neurotoxic kynurenine metabolites, exacerbating neuronal damage.
Recombinant KYNU protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable high-purity, scalable production for research and therapeutic exploration. Its recombinant form retains enzymatic activity and structural integrity, allowing studies on substrate specificity, inhibitor screening, and structural biology. Researchers leverage this tool to investigate KYNU’s role in disease mechanisms, identify biomarkers, and develop targeted therapies. Recent studies also explore its potential in modulating the tumor microenvironment or mitigating neuroinflammation.
Overall, KYNU recombinant protein serves as a vital resource for dissecting the kynurenine pathway’s complexity and advancing translational research in neurology, oncology, and immunology.
×
